Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron and Pioglitazone for Brown Fat Activation
NCT02919176Phase 1Completed
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in obesity and metabolic syndrome comparing Mirabegron, Pioglitazone and Mirabegron + Pioglitazone (3 arms). Primary endpoints: Change in beige adipose tissue at 10 weeks, Change in brown adipose tissue at 10 weeks and 1 more. Started Sep 2016; status: completed.
02
Drugs
mirabegronpioglitazone
03
Conditions
obesitymetabolic syndrome
Beyond the preview
Go deeper on NCT02919176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919176.